retatrutide and type 1 diabetes Medscape | The investigational triple GLP-1/GIP/glucagon receptor agonist produced significant weight loss A1c reduction in people Eli Lilly's retatrutide shows promising

BPC-157 is commonly used daily for 4-8 week cycles based on preclinical safety data showing no adverse effects at therapeutic doses

DNA damage-how and why we age

Semaglutide Semaglutides mechanism of action is very different but still impactful

This is a carefully sequenced protocol designed to open drainage pathways before mobilizing toxins, push toxins through Phase I and II liver detox, and capture them in the GI tract for elimination

Then they found the secondary benefit of reducing their alcohol use, and their liver disease is starting to heal. The stimulant addiction study is a two-phase pilot that began in January with an initial 25 participants

[DOI] [PubMed] [Google Scholar] 134.Sellman J.E., DeRuisseau K.C., Betters J.L., Lira V.A., Soltow Q.A., Selsby J.T., Criswell D.S